Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
This article was originally published in The Gray Sheet
Executive Summary
Heart failure device trials should be powered to measure differences in mortality compared with the control, even if mortality reduction is not the therapy's primary goal, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD
You may also be interested in...
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel